Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Edwards Lifesciences sent a formal request to CMS in February after its Evoque TTVR device gained FDA approval. The agency is now accepting public comments for 30 days.
Hydra TAVR valve gains key approval as global reach continues to grow
The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.
SAVR outperforms TAVR in patients with bicuspid aortic valves
BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.
Treating AFib patients with TAVR still linked to elevated risks
While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.
Heart surgeons detail world’s first robotic heart procedure of its kind
The care team behind the very first robotic aortic valve replacement and coronary artery bypass surgery has written about the experience in The Annals of Thoracic Surgery. The group discussed the development of the technique, how the patient was chosen for treatment and other key details.

Anjali Owens, MD, medical director, Center for Inherited Cardiac Disease, associate professor of medicine at the Hospital of the University of Pennsylvania, discusses the need for standardization in HCM care. #ASE #ASE23 #ASE2023 #HCM

More consistency, standardization still needed when treating HCM

Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained.

August 4, 2023

The 25 best U.S. cardiology hospitals ranked

U.S. News & World Report's annual rankings of heart hospitals named Cleveland Clinic No. 1, once again, but there were many changes among the other top 25 hospitals.

August 2, 2023

The team that implanted the first TaurusTrio TAVR valve at Beijing An Zhen Hospital, Capital Medical University in July 2023.

Chinese made version of JenaValve TAVR device implanted in first patient

The first patient was enrolled in a multicenter clinical trial for the TaurusTrio transcatheter aortic valve replacement system, used for aortic regurgitation.

August 1, 2023

Abbott pulled the Trifecta GTaortic surgical valve off market in July 2023 after it was determined it had early structural valve deterioration (SVD) before 5 years.

Abbott pulls Trifecta heart valves off the market due to early deterioration

The FDA sent notice today that Abbott is pulling the Trifecta aortic surgical heart valve off the U.S. market due to the risk of early structural valve deterioration in less than 5 years.

July 31, 2023